Results 1 to 10 of about 18,139 (185)

Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report. [PDF]

Pharmacy (Basel)
Background: Uremic pruritus is one of the most debilitating complications among patients with end-stage kidney disease (ESKD) receiving hemodialysis.
Rungkitwattanakul D, Brooks M, Adesina S, Belrhiti S, Chaijamorn W, Charoensareerat T, Nwaogwugwu U, Mere C.   +7 more
europepmc   +2 more sources

Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers. [PDF]

Commun Med (Lond)
Background The relative efficacies of nalmefene versus naltrexone for alcohol use disorder is the subject of intense and ongoing debate. The two pan-opioid receptor ligands differ primarily in actions at the kappa opioid receptor, where naltrexone acts ...
Farahbakhsh ZZ, Brown AR, Nolan SO, Mukerjee S, Siciliano CA.   +4 more
europepmc   +2 more sources

Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study.

JMIR Res Protoc
BackgroundNaltrexone is an opioid receptor antagonist. Naltrexone is used to block the euphoric and sedative effects of drugs such as heroin, codeine, and morphine.
Muhamad NA, Ma'amor NH, Muhamad Rasat MA, Tengku Baharudin Shah TPN, Rosli '', Leman FN, Jamalluddin NH, Misnan NS, Chemi N, Abdullah N, Ibrahim N, My Addiction Study group.   +11 more
europepmc   +2 more sources

Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study

Archives of Academic Emergency Medicine, 2022
Introduction: Opioids have been the leading cause of death from poisoning in Iran for several years. This study aimed to evaluate the clinical and para-clinical presentations of naltrexone intoxication, its toxic dose, and its epidemiological properties.
Mitra Rahimi, Alireza Kargar, Delara Hazegh Fetratjoo, Sayed Masoud Hosseini, Arezou Mahdavinejad, Shahin Shadnia   +5 more
doaj   +1 more source

Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey

Frontiers in Psychiatry, 2022
ObjectiveTo survey barriers in prescribing naltrexone for alcohol use disorder.MethodsA 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family ...
Jonathan G. Leung, Prasanna P. Narayanan, Matej Markota, Nathaniel E. Miller, Kemuel L. Philbrick, M. Caroline Burton, Robert W. Kirchoff   +6 more
doaj   +1 more source

Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. [PDF]

PLoS ONE, 2012
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure.
Waleed O Farid, Andrew J Lawrence, Elena V Krstew, Robert J Tait, Gary K Hulse, Sarah A Dunlop   +5 more
doaj   +1 more source

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis

Frontiers in Psychiatry, 2022
BackgroundOpioid dependency is a chronic relapsing disorder for which different therapeutically interventions have been developed. Naltrexone is a non-selective opioid antagonist that can be utilized for maintenance therapy in opioid dependency.
Moein Zangiabadian, Saeid Golmohammadi, Seyed Aria Nejadghaderi, Mohammad Mahdi Zahmatkesh, Mohammad Javad Nasiri, Majid Sadeghian   +5 more
doaj   +1 more source

Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease

Hepatology Communications, 2022
Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in those with LD.
Divya Ayyala, Thomas Bottyan, Christine Tien, Michael Pimienta, Jennie Yoo, Kelli Stager, Jose Luis Gonzalez, Andrew Stolz, Jennifer L. Dodge, Norah A. Terrault, Hyosun Han   +10 more
doaj   +1 more source

Naltrexone Implant for Opioid Use Disorder

Neurology International, 2021
The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic.
Amber N. Edinoff, Catherine A. Nix, Claudia V. Orellana, Samantha M. StPierre, Erin A. Crane, Blaine T. Bulloch, Elyse M. Cornett, Rachel L. Kozinn, Adam M. Kaye, Kevin S. Murnane, Alan D. Kaye   +10 more
doaj   +1 more source

Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol

Neurobiology of Disease, 2009
The opioid antagonist naltrexone is the standard pharmacotherapy for alcoholism, although compliance is often low. The mechanism by which naltrexone reduces drinking is yet unclear.
Jennifer M. Mitchell, Lindsey J. Bergren, Katherine S. Chen, Michael C. Rowbotham, Howard L. Fields   +4 more
doaj   +1 more source